Novo EVP says new data shows Wegovy stands out in obesity crowd

With sustained weight loss over a two-year period, Novo Nordisk's Wegovy has differentiated itself from existing competitors on the obesity drug market, says Novo Nordisk's EVP Martin Holst Lange. He also thinks the new results could help change the perception of obesity treatment.

Photo: Novo Nordisk / PR

Novo Nordisk can celebrate obesity drug Wegovy, which is built on the GLP-1 analog semaglutide, as it has demonstrated a significant and sustained weight loss of 15.2 percent in a two-year study.

"What is interesting to me is to see that the weight loss we have reported so far, which has been around 15-17 percent, is the same we're seeing after two years," Executive Vice President, Development at Novo Nordisk Martin Holst tells MedWatch about the results from the company's Step 5 study, which were presented last week during this year's Obesity Week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs